Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Biocon secures USFDA approval for Pebrilzo, its fifth cancer biosimilar

Biocon also said it has secured a global settlement and licence agreement with Genentech, allowing Pebrilzo's earliest licensed US launch in 2028.

Biocon secures USFDA approval for Pebrilzo, its fifth cancer biosimilar

We haven't written up this one. Business Standard IN has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Every outlet that reported this, and when →

Read the original at business-standard.com →

More in Health & Medicine

More from Monday 16 November →